Patent · US Active

Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer

US9387192B2 · kind B2 · utility

0Cited by

2References

12Claims

0Family size

Assignee

DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUM · DE

Inventors

Min LI-WEBER · Bad Dürkheim, DE
Peter Krammer · Heidelberg, DE

Key dates

Filing date	Nov 20, 2009
Grant date	Jul 12, 2016
Priority date	—
Expiry date	Jan 30, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a combined preparation comprising at least one rocaglamide derivative and at least one apoptosis inducing agent, preferably from the group of substances comprising agents inducing the extrinsic apoptotic pathway, antiproliferative agents and agents which induce apoptosis in T-cells by activation induced cell death (AICD) for the treatment of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.